Law Office of Brodsky & Smith, LLC Announces Settlements of Yaz, and Yasmin Cases

BALA CYNWYD, Pa., Aug. 2, 2012 /PRNewswire/ -- Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against Bayer AG ("Bayer") (XETRA- BAYN.DE) and Barr Laboratories, Inc. ("Barr"") on behalf of individuals that suffered an adverse side effect while taking Yaz or Yasmin, and their generic version Ocella, such as blood clots, deep vein thrombosis, strokes, or a heart attacks.

Bayer has announced that it has reached agreements to settle cases with a total of 1,877 claimants that used these combinational oral contraceptives that contained both estrogen and progestins not found in other oral contraceptives. Bayer has also reported that there are 13,530 claimants remaining that they currently know of in the U.S. and that they expect both the number of claimants and settled cases to continue to grow. On April 10, 2012, the US Food and Drug Administration announced that Bayer's Yaz birth-control pill and similar medications may carry a higher risk of blood clots than other pills.  

If you or a family member have suffered a serious injury or a loved one died after taking Yaz, Yazmin, or Ocella and you wish to discuss the legal ramifications of these settlements or your right to obtain compensation, or have any questions, you may e-mail or call the law office of Brodsky & Smith, LLC who will, without obligation or cost to you, attempt to answer your questions.  You may contact Jason L. Brodsky, Esquire or Evan J. Smith, Esquire at Brodsky & Smith, LLC, Two Bala Plaza, Suite 602, Bala Cynwyd, PA 19004, by e-mail at [email protected], or by calling toll free 877-LEGAL-90.

 

SOURCE Brodsky & Smith, LLC

Launch Readiness

Optimize cross-functional collaboration and engage with key stakeholders for the successful launch of a product

Join the Launch Readiness for Medical Affairs & Communications Teams Summit to learn best practices in taking a structured approach to enhance medical affairs activities surrounding a launch and increase knowledge and communication with thought leaders.